Další formáty:
BibTeX
LaTeX
RIS
@article{923964,
author = {Stager, G. G. and Abrahámová, J. and Bacanu, F. and Brincat, S. and Brize, A. and Cesas, A. and Cufer, T. and Dank, M. and Duchnowska, R. and Eniu, A. and Jassem, J. and Kahan, Z. and Matos, E. and Padrik, P. and Plate, S. and Pokker, H. and Purkalne, G. and Timcheva, C. and Tzekova, V. and Vyzula, Rostislav and Zielinski, CH.C.},
article_location = {Wien},
article_number = {11-12},
doi = {http://dx.doi.org/10.1007/s00508-010-1373-6},
keywords = {TYROSINE KINASE INHIBITOR; TRASTUZUMAB TREATMENT OPTIMIZATION; PHASE-II TRIAL; TARGETED THERAPIES; 1ST-LINE TREATMENT; CLINICAL-TRIALS; POOLED ANALYSIS; RECEPTOR; GROWTH; CELLS},
language = {eng},
issn = {0043-5325},
journal = {Wiener Klinische Wochenschrift},
title = {Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel},
volume = {122},
year = {2010}
}
TY - JOUR
ID - 923964
AU - Stager, G. G. - Abrahámová, J. - Bacanu, F. - Brincat, S. - Brize, A. - Cesas, A. - Cufer, T. - Dank, M. - Duchnowska, R. - Eniu, A. - Jassem, J. - Kahan, Z. - Matos, E. - Padrik, P. - Plate, S. - Pokker, H. - Purkalne, G. - Timcheva, C. - Tzekova, V. - Vyzula, Rostislav - Zielinski, CH.C.
PY - 2010
TI - Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel
JF - Wiener Klinische Wochenschrift
VL - 122
IS - 11-12
SP - 368-379
EP - 368-379
PB - Springer
SN - 00435325
KW - TYROSINE KINASE INHIBITOR
KW - TRASTUZUMAB TREATMENT OPTIMIZATION
KW - PHASE-II TRIAL
KW - TARGETED THERAPIES
KW - 1ST-LINE TREATMENT
KW - CLINICAL-TRIALS
KW - POOLED ANALYSIS
KW - RECEPTOR
KW - GROWTH
KW - CELLS
N2 - In breast cancer, early detection as well as new developments in therapeutic options has resulted in less patients presenting with metastatic disease. However, about one-third of women with early stage breast cancer will eventually develop metastatic disease. Furthermore, approximately 20-30% of patients with breast cancer have tumors that overexpress human epidermal growth factor receptor (HER-2), which is associated with an aggressive tumor phenotype and poor prognosis. The identification of the HER-2 protein led to the development of highly effective therapeutics directed at this receptor. Trastuzumab, a recombinant, humanized, monoclonal antibody that binds to the extracellular domain of the HER-2 protein, has shown significant clinical benefit in metastatic and early-stage HER-2-positive breast cancer. Since the cancer recurs after adjuvant therapy in some women, and metastatic breast cancer eventually develops resistance to trastuzumab, there is a need for alternative treatment modalities to block HER-2 signaling. One of these treatment options is lapatinib, an orally active small molecule that inhibits the tyrosine kinases of HER-2 and the epidermal growth factor receptor type 1 (EGFR). In this consensus statement current treatment options in metastatic and locally advanced disease are discussed with a special focus on lapatinib.
ER -
STAGER, G. G., J. ABRAHÁMOVÁ, F. BACANU, S. BRINCAT, A. BRIZE, A. CESAS, T. CUFER, M. DANK, R. DUCHNOWSKA, A. ENIU, J. JASSEM, Z. KAHAN, E. MATOS, P. PADRIK, S. PLATE, H. POKKER, G. PURKALNE, C. TIMCHEVA, V. TZEKOVA, Rostislav VYZULA a CH.C. ZIELINSKI. Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. \textit{Wiener Klinische Wochenschrift}. Wien: Springer, roč.~122, 11-12, s.~368-379. ISSN~0043-5325. doi:10.1007/s00508-010-1373-6. 2010.
|
